Reckitt Won the First NEC Bellwether. What That Actually Prices

A jury in the US District Court for the Northern District of Illinois returned a unanimous verdict in favour of Reckitt's Mead Johnson unit in Inman v. Mead Johnson & Company, clearing the company of liability in a case alleging that its Enfamil preterm infant formula caused necrotising enterocolitis. This was the first bellwether tried against Mead Johnson in the federal multidistrict litigation. Reckitt shares rose about 4.3% on Tuesday 1 September 2026 from a prior close of 5,132p, adding well over £1bn of market value and putting the stock at the top of the FTSE 100 on a day the index itself fell.

So the direct answer to why the Reckitt share price rose is a courtroom result, not a trading statement. But the more useful answer is that a single defence verdict removed the most severe interpretation of a liability the market had been carrying at an unknown size. Mead Johnson now states that there are no outstanding jury verdicts against it in the overall NEC litigation. That is a meaningful statement — and a narrower one than it first reads, which is where the analysis has to start.

What actually happened

Bellwether trials exist to price litigation. In a multidistrict proceeding with a large number of broadly similar claims, a small set of representative cases is tried first, and both sides read the outcomes to work out what the remaining inventory is worth in settlement. A defence verdict in the first federal bellwether is therefore genuinely informative: it establishes that a jury, presented with the plaintiffs' strongest available science, was not persuaded. Mead Johnson's own framing was that the allegations "were not supported by the science or experts in the medical community".

What it does not establish is the outcome of the litigation. Well over 700 claims are consolidated in the federal MDL in the Northern District of Illinois, with hundreds more filed in state courts. One verdict, however unanimous, is one data point against a docket of that size — and the docket has been growing, not shrinking.

The qualifier that matters most is the phrase "no outstanding jury verdicts". Mead Johnson has previously been hit with a $60m award in Illinois state court over the same product — a verdict an Illinois appellate court reversed in June 2026, granting a new trial. The state-court and federal tracks run separately, and juries in the parallel Similac litigation against Abbott have returned very large awards. So the accurate statement is not that Mead Johnson has never lost; it is that it does not currently carry an unresolved adverse verdict. That is a real improvement in position. It is not the same as vindication, and treating it as such is how a 4.3% move becomes a 15% one on no new information.

J.P. Morgan upgraded the shares to overweight from neutral on the same morning. It is worth naming that for what it is: a broker changing its stance hours after a public verdict is reacting to the same news the market is, and it should be read as an amplifier of Tuesday's move rather than as independent evidence about Reckitt's value.

Why the market reacted the way it did

Reckitt has traded at a persistent discount to its consumer-health peers, and the interesting question is what that discount has actually been pricing. There are two candidate explanations and they have very different implications.

The first is litigation. An open-ended liability of unquantifiable size is close to un-modellable, and markets apply a blunt haircut to businesses carrying one. On this reading, the discount is a litigation provision imposed by the market rather than the accounts, and each favourable data point releases some of it. Tuesday's 4.3% is consistent with that: a partial release, not a full one.

The second explanation is that the discount is about the Nutrition business itself. Look at the first-half 2026 numbers. Reckitt delivered like-for-like net revenue growth of 2.6% for the group, with Core Reckitt at 2.7% and a Q2 acceleration to 4.7%. Mead Johnson's like-for-like net revenue grew 2.0% — the slowest-growing part of the portfolio, in a category facing structural pressure from birth rates in its key markets. Reported group revenue fell 8.1% to £6.41bn, reflecting the Essential Home disposal, and adjusted diluted EPS of £1.521 was down 9.7%, driven by the lost Essential Home income and higher input costs in both Core Reckitt and Mead Johnson.

Those two explanations point in opposite directions. If the discount is litigation, a clean run of MDL outcomes re-rates the whole group. If the discount is Nutrition's own economics — a low-growth business in a shrinking category — then removing the litigation overhang does not re-rate anything; it simply makes the asset easier to sell. The honest read is that it is both, and Tuesday's move suggests the market thinks the litigation component is the smaller of the two.

The Openbook read

Reward/Risk is the factor this event actually touches, and the change is narrower than the headline. What a first defence verdict does is truncate the worst tail — it makes the scenario in which Mead Johnson faces a cascade of large adverse federal verdicts less probable. It does not change the central case much at all, because the central case was always some negotiated resolution across a large claim inventory at a cost well below the tail. The distribution got tighter on the downside; the median barely moved. That is worth something, and it is worth roughly what the market paid for it.

Growth is unchanged and remains the group's weakest suit. A 2.6% like-for-like half, with Mead Johnson at 2.0%, is a low-growth consumer business. The Q2 acceleration to 4.7% is the encouraging detail and the one to test in the next print. Nothing that happened in an Illinois courtroom alters this factor.

Profitability is under pressure on the reported numbers, with adjusted diluted EPS down 9.7% in the half. Some of that decline is mechanical — Essential Home was sold on 31 December 2025 and its earnings left with it — but management flagged higher input costs in both Core Reckitt and Mead Johnson as a genuine drag. The offset is the stated plan to cut annual fixed costs from around 22% of revenue to 19% by 2027, which is where the medium-term profitability case sits.

Solvency is comfortable and has been actively managed. Reckitt returned £3.0bn to shareholders in the first half, including a £1.6bn special dividend funded by the Essential Home disposal, completed a £1.0bn buyback and announced a further £500m programme, while lifting the interim dividend 5% to 88.6p. A company returning capital at that pace is not one whose balance sheet is braced for a litigation shock — which is itself a statement of management's confidence, and a data point worth weighing alongside the verdict.

Momentum improves on the day but from a weak base. Reckitt has been a laggard in a sector that has itself lagged, and a single session at the top of the index does not reverse that. Momentum scores respond to trend, and one verdict does not make one.

The read-across

The most direct read is to Abbott, which faces the parallel Similac litigation over the same alleged mechanism in the same court system. A defence verdict for Mead Johnson on the general causation science is not binding on Abbott's cases, but it is evidence about how juries respond to the underlying scientific argument, and both companies are defending the same core proposition — that cow's-milk-based preterm formula causes NEC. Abbott has faced considerably more adverse jury outcomes than Mead Johnson to date, so the read-across is directional rather than symmetrical.

The second read is to the UK consumer staples complex more broadly. Reckitt, Unilever and Haleon have all spent the past few years being valued on the credibility of their portfolio reshaping rather than on their organic growth rates, which cluster in the low single digits. Reckitt is the furthest into that process — Essential Home is gone, Mead Johnson is under consideration for sale, and the stated destination is a concentrated group of eleven powerbrands. A cleaner litigation position makes Nutrition materially easier to sell, and the strategic value of Tuesday's verdict may ultimately be larger than its valuation impact.

For the FTSE 100 itself, the move is a reminder of how much of the index's single-stock volatility now comes from US legal and regulatory outcomes rather than domestic trading conditions. You can compare the UK consumer names on growth, returns and balance-sheet strength using our screener.

What to watch next

• The next bellwether trials in the federal MDL. One verdict prices very little; a sequence prices the docket. The pattern across the next two or three federal cases is what determines whether the market treats the litigation as resolved-in-principle or merely paused.
• State-court cases. These run on a separate track and have historically produced the adverse outcomes, including the $60m award against Mead Johnson. A federal defence win does not protect against a state-court loss, and one would test how much of Tuesday's move was durable.
• Any development on a Mead Johnson sale. Reckitt has been open about considering a disposal of the Nutrition division. A cleaner litigation position changes what a buyer will pay and whether indemnities can be structured — this is the single largest potential catalyst in the story.
• Q3 and full-year trading. The test is whether Q2's 4.7% like-for-like acceleration was the start of a trend or a comparator effect, and whether the input-cost pressure flagged in the first half eases.
• Progress on the fixed-cost programme. The path from roughly 22% to 19% of revenue by 2027 is where the profitability recovery has to come from, and it should be visible in margin disclosure well before 2027.

Openbook covers Reckitt Benckiser alongside UK consumer peers including Haleon and Unilever, with the five-factor scores updated as results and events land.